RESEARCH ARTICLE

Human herpesvirus multiplex ddPCR detection in brain tissue from low- and high-grade astrocytoma cases and controls

Cheng-Te Major Lin1,2, Emily C. Leibovitch1,2, M. Isabel Almira-Suarez2 and Steven Jacobson1*

Abstract

Background: Glioblastoma (GBM) is a fatal CNS malignancy, representing 50 % of all gliomas with approximately 12–18 months survival time after initial diagnosis. Recently, the human herpesvirus cytomegalovirus (CMV) has been suggested to have an oncogenic role, yet this association remains controversial. In addition, human herpesvirus 6 (HHV-6) and Epstein-Barr virus (EBV) have also been associated with low-grade gliomas, but few studies have examined HHV-6 and EBV in glioblastomas. Droplet digital PCR (ddPCR) is a highly precise diagnostic tool that enables the absolute quantification of target DNA. This study examines the association between multiple human herpesviruses and astrocytomas.

Methods: This study analyzed 112 brain tissue specimens, including 45 glioblastoma, 12 astrocytoma grade III, 2 astrocytoma grade II, 4 astrocytoma grade I, and 49 controls. All brain tissue samples were de-identified and pathologically confirmed. Each tissue block was sectioned for DNA extraction and CMV, EBV, HHV-6A and HHV-6B, and a cellular housekeeping gene were amplified by ddPCR.

Results: Neither CMV nor HHV-6A were detected in any of the astrocytoma samples. However, HHV-6B (p = 0.147) and EBV (p = 0.049) had a higher positivity frequency in the GBM compared to the controls.

Conclusion: The undetectable CMV DNA in the astrocytoma cohort does not support the observation of an increased prevalence of CMV DNA in GBM, as reported in other studies. EBV has a significantly higher positivity in the GBM cohort compared to the controls, while HHV-6B has a higher but not statistically significant positivity in the case cohort. Whether these viruses play an oncogenic role in GBM remains to be further investigated.

Keywords: CMV, HHV-6A, HHV-6B, EBV, Herpesvirus, Astrocytoma, Glioblastoma, ddPCR

Background

Gliomas are brain tumors that develop from glial cells. Approximately a quarter of diagnosed gliomas are astrocytomas, which are scaled from grade I to grade IV based on histological features [1]. According to the World Health Organization (WHO) classification for CNS tumors: astrocytoma grade I and astrocytoma grade II are classified as low-grade astrocytomas, while astrocytoma grade III and astrocytoma grade IV are classified as high-grade astrocytomas. Furthermore, astrocytoma grade IV is also referred to as glioblastoma (GBM). Patients with GBM have a median survival of 12 months and an average 5-years survival rate less than 5 % [2, 3]. Although GBM has been extensively studied in clinical and laboratory settings, there are limited effective treatments for this malignant tumor [4]. The herpesviruses are large, enveloped, double-stranded DNA viruses. Currently, there are more than 100 known herpesviruses, and nine human herpesviruses (HHVs) that can cause a wide range of diseases. The β-herpesvirus subfamily, one of three herpesvirus subfamilies, has been suggested to be associated with central nervous system (CNS) impairments and diseases, such as hearing loss, CNS inflammation, and primary brain tumors. Recently, accumulating evidence indicates that...
cytomegalovirus (CMV), a β-herpesvirus, is associated with GBM, but these reports remain controversial [5, 6]. For example, some studies have demonstrated CMV viral genome expression in glioblastoma samples compared to other types of non-neurological disease patients, whereas other have found no trace of CMV DNA in glioblastoma. The discrepancy between these findings may be contributed by differences in the experimental methodology, brain tissue specimen preservation, and DNA detection methods [7]. The vast majority of studies were done by PCR or immunohistochemistry, which focused on the molecular identification of viral DNA or viral proteins, respectively. Such discrepancy encourages a more in-depth investigation of the role of CMV and its association with glioblastoma.

Another human β-herpesvirus, human herpesvirus 6 (HHV-6) has also been associated with low-grade gliomas [8–10], but few studies have examined HHV-6 in glioblastomas. There are two species of HHV-6, HHV-6A and HHV-6B. Both viruses differ in their epidemiological, biological, and molecular properties. Less is known about the specificity of HHV-6A-associated diseases compared with HHV-6B, which is the etiologic agent of roseola, and associated with CNS diseases such as status epilepticus, mesial temporal sclerosis, and multiple sclerosis [11–13]. Another subfamily of human herpesviruses, the γ-herpesviruses, establishes latent infection in B-lymphocytes and may cause these cells to proliferate abnormally, leading to Kaposi’s sarcoma and CNS lymphoma [14]. Epstein-Barr virus (EBV) is thought to be associated with specific oncogenic conditions, such as Hodgkin’s lymphoma, Burkitt’s lymphoma, nasopharyngeal carcinoma and a subset of gastric carcinomas [15]. EBV genomic DNA has also been detected in high-grade glioma samples by unmapped next-generation sequencing, but mechanisms of pathogenesis are still unclear [16]. Overall, the extent to which human herpesviruses are associated with GBM is currently unknown.

More recently, a randomized and blinded clinical trial examined the effectiveness of a CMV vaccine (CMV pp65 RNA pulsed DCs) with different pre-conditioning regimens for treating GBM. Aside from identifying an immunogenic preconditioning regimen, the study demonstrated that an increase in CMV pp65-specific immune responses correlated with overall GBM survival [17]. Although these clinical trials have shown promising results regarding positive clinical outcomes for GBM patients, the significance of CMV in GBM remains controversial [18]. However, this study provides clinical evidence that anti-viral therapies can improve patient outcomes, which suggests that viruses, specifically herpesviruses, might play a role in these malignant brain tumors.

To investigate the presence of herpesvirus genome sequences in different grades of astrocytomas and controls, we utilized a novel methodology to detect and quantify multiple human herpesviruses. Droplet digital PCR (ddPCR) is a newly developed technology that divides PCR reactions into tens of thousands droplets and detects the amplification in each droplet, which enables us to detect and quantify target DNA directly [19, 20]. Other studies have used this highly precise technology to detect bacterial or viral genomic DNA sequences in various types of samples [21–23]. To quantify multiple human herpesviruses in astrocytoma brain tissue specimens and non-neurological disease control specimens, we developed a multiplexing method, which enables the simultaneous screening of multiple target sequences in brain tissue samples.

This study quantitated CMV, HHV-6A, HHV-6B and EBV viral DNA in astrocytoma (WHO grade I-IV) and non-neurological disease control tissues with a newly developed ddPCR multiplexing method.

**Methods**

**Study design**
This was a retrospective and health center-based study. The study screened for multiple human herpesviruses (CMV, HHV-6A, HHV-6B, and EBV) in different grades of astrocytomas and non-neurological disease controls, which excluded other brain cancers and other CNS diseases.

Samples were obtained from the George Washington University Hospital and the National Institutes of Health, and the protocol was approved by both institutional review boards. The study collected specimens preserved by three different methods: formalin-fixed paraffin embedded (FFPE), optimal-cutting temperature (OCT), and fresh frozen. Study brain tissue specimens were selected based on medical records from the institutions. A total of 112 unique adult brain tissue samples were included in the study. The study collected astrocytomas (WHO grades I-IV) and non-neurological disease controls. The astrocytoma FFPE cases were comprised of four grade I, one grade II, two grade III, and 19 grade IV (GBM). Also, there were ten grade III astrocytomas and 20 grade IV (GBM) collected as the OCT bio-preserved tissue. Lastly, there was a total of six fresh frozen astrocytomas grade IV (GBM) and one fresh frozen astrocytoma grade II. Non-neurological disease tissue specimens were selected based on medical records from both institutes. These controls were obtained from autopsy tissue specimens, which were not associated with neurological disease as cause of death. There were 49 non-neurological disease brain specimens, comprised of 32 fresh frozen samples and 17 FFPE-preserved samples (Table 1). The fresh frozen control samples were
### Table 1 Age, sex, cause of death for non-neurological disease controls (n = 49)

| Age (years) | Sex | Cause of death                      |
|-------------|-----|-------------------------------------|
| Fresh Frozen Tissue |     |                                     |
| 33          | M   | Coronary Artery Thrombosis          |
| 34          | F   | Asthma                              |
| 64          | M   | ASCVD                               |
| 50          | M   | ASCVD                               |
| 34          | M   | Abdominal Injuries                  |
| 48          | M   | HASCVD                              |
| 64          | F   | ASCVD                               |
| 43          | F   | HASCVD                              |
| 30          | M   | Multiple Injuries                   |
| 34          | M   | HASCVD                              |
| 40          | F   | Multiple Injuries                   |
| 43          | F   | HASCVD                              |
| 52          | M   | ASCVD                               |
| 49          | M   | Pulmonary Thromboembolism           |
| 59          | M   | Bronchopneumonia                    |
| 40          | F   | Pulmonary Embolism                  |
| 28          | M   | ARVC                                |
| 53          | M   | HASCVD                              |
| 44          | M   | HASCVD                              |
| 50          | F   | HASCVD                              |
| 35          | F   | Streptococcal Sepsis                |
| 48          | F   | HASCVD                              |
| 37          | M   | ASCVD                               |
| 63          | F   | Acute Myocardial Infarction         |
| 23          | M   | Hypertrophic Cardiomyopathy         |
| 56          | F   | Asthma                              |
| 27          | M   | ASCVD                               |
| 57          | M   | ASCVD                               |
| 54          | F   | ASCVD                               |
| 63          | M   | HASCVD                              |
| 36          | M   | ASCVD                               |
| 60          | F   | HASCVD                              |
| FFPE-Preserved Tissue |     |                                     |
| 74          | F   | Breast Cancer                       |
| 64          | M   | Lipoid Pneumonia                    |
| 56          | M   | Ascending Aortic Dissection         |
| 43          | M   | Acute Pneumonia                     |
| 64          | F   | Acute Ischemic Bowel Disease        |
| 63          | F   | Congestive Heart Failure            |
| 65          | M   | Laryngeal Squamous Cell Carcinoma   |
| 86          | M   | Acute Abdominal Compartment Syndrome|
| 41          | M   | P. aeruginosa Sepsis                |
| 68          | F   | Acute Fibrinous and Organizing Pneumonia |
Brain tissue DNA extraction

Formalin-Fixed Paraffin Embedded (FFPE)

FFPE brain tissue genomic DNA was extracted using the QIAamp DNA FFPE Tissue kit (Qiagen, Valencia, CA). A total of 500 μm (ten sections 50 μm thick) of FFPE tissue was used in the genomic DNA extraction, which was performed according to the manufacturer’s specifications. Samples were eluted with 100 μl of buffer AE.

Optimal-Cutting Temperature (OCT)

OCT brain tissue genomic DNA was extracted using the QIAamp DNA Mini kit (Qiagen, Valencia, CA). A total of 500 μm (ten sections 50 μm thick) of OCT tissue was used in the genomic DNA extraction. The OCT compound was dissolved in 1 ml of PBS (Ca-Mg free) and spun at 8000 rpm for 5 min. PBS washes were repeated if the samples had significant remaining amounts of OCT. Samples were eluted with 100 μl of buffer AE.

Fresh frozen

Fresh frozen brain tissue genomic DNA was extracted by the DNeasy Blood and Tissue kit (Qiagen, Valencia, CA). A total of 25 mg of fresh frozen brain tissue was used in the genomic DNA extraction, performed according to the manufacturer’s instructions. Samples were eluted with 100 μl of buffer AE.

Multiplex digital droplet PCR assay

The CMV, EBV, and HHV-6 primers were selected from highly conserved regions, ul55, lmp1, and u57, respectively (Table 2) [24–27]. Different probes were used to distinguish between HHV-6A (FAM) and HHV-6B (VIC), as described by Leibovitch et al. in 2014 [25]. The 20X ddPCR primer/probe solution was composed of 18 μl of 100 μM forward primer, 18 μl of 100 μM reverse primer, 5 μl of 100 μM probe (FAM or VIC), and 79.5 μl PCR quality distilled water. With the multiplexing method, the 10X ddPCR primer/probe solution was composed of 9 μl of 100 μM forward primer, 9 μl of 100 μM reverse primer, 2.5 μl of 100 μM probe (FAM or VIC), and 59 μl PCR quality distilled water. The ddPCR primer/probe concentration difference generated distinct populations on the Y-axis. HHV-6A, HHV-6B, and rpp30 were detected with the 20X ddPCR mastermix solution; meanwhile, CMV and EBV were detected with the 10X ddPCR mastermix solution. Each plot displayed the viruses or the housekeeping gene (rpp30) populations in a brain tissue specimen. rpp30 (NCBI gene 10556) is an housekeeping gene, which was used as a human genome reference loci, and served as an indicator of brain tissue DNA quality and cellular quantity. A specimen was considered positive when the 2-D fluorescence plots showed at least two dots at the expected amplitude. Each multiplex positive sample was further confirmed by a singleplex ddPCR assay, which targeted only one genomic sequence per axis. Samples were considered positive only if both multiplex and singleplex assays showed equal or more than two droplets at the expected amplitude. More detailed multiplex ddPCR method is provided by the Bio-Rad ddPCR guidelines [20]. The viral load calculation and statistical analysis were based on the multiplex ddPCR assay.

Statistical analysis

With the retrospective study design, we computed the positivity frequency proportions in cases and controls to examine the proportional differences between each human herpesvirus and different grades of astrocytoma or other neurological diseases.
controls. p-value at 95 % confidence level is presented in each group. Based on the Fisher’s Exact test, we included the p-value to determine statistically significant proportions between cases and controls. We used RStudio software 0.99.486 version developed by RStudio, Inc. and Prism 6 developed by GraphPad software, Inc to analyze the data.

Results

ddPCR multiplex assay characterization

The present study optimized the CMV ddPCR assay by comparing three published CMV primers and probe sets [24, 28, 29]. After adjusting the published sequences to fit ddPCR parameters, one primer/probe set had a high GC content that impeded efficient amplification of target sequences [29]. Therefore, two CMV primer/probe sets were compared for sensitivity and performance in the ddPCR assay (Fig. 1a and c). Though both detected CMV positivity in the positive control, one set generated a tighter, higher amplitude positive population (Fig. 1a), suggesting greater target DNA affinity compared to the other CMV primer/probe set, which generated a more scattered positive population (Fig. 1c). Therefore, the ddPCR-adapted CMV primer/probe set shown in Fig. 1a was used for this study and multiplexed with HHV6A, HHV6B, and EBV. The HHV-6A and HHV-6B primer/probe sets were described in a recent study of co-infection [25]. The EBV primer/probe set was adapted from published sequences [27] and optimized to fit ddPCR-specific parameters (unpublished data). The results in Fig. 1c and d are representative of these combinations. Clear separations can be seen with HHV-6A and CMV on the FAM channel (Y-axis) and HHV-6B on the VIC channel (X-axis) (Fig. 1b). Likewise, distinct populations are seen with EBV on the FAM channel (Y-axis) and RPP30 on the VIC channel (X-axis) (Fig. 1d). These data show that successful herpesvirus multiplex ddPCR can be achieved, with detection sensitivities that are comparable to singleplex ddPCR (data not shown) [24, 25].

Undetectable CMV viral genome sequences in GBM

Each astrocytoma case was screened for CMV by both the multiplex and singleplex ddPCR assays. All clinical tissue specimens were collected either as FFPE, OCT, or fresh frozen biopreservation methods. Within each astrocytoma case cohort and non-neurological disease control cohort, there was no frequency difference in CMV detection by ddPCR assay between these preservation methods. Furthermore, no CMV reactivity was observed in any tissue specimens when assayed by either a singleplex or multiplex ddPCR. As shown in Table 3, the present study did not detect CMV genomic DNA in any astrocytoma case (n = 63) with either ddPCR assay, although one FFPE non-neurological disease tissue specimen showed CMV positivity with a viral load of 9023 copies/10⁶ cells (Fig. 2). Collectively, the absence of CMV DNA in our GBM cohort does not support an association of CMV and glioblastoma.

High HHV-6B positivity frequency in astrocytomas

By contrast with CMV, HHV-6B was detected at a relatively high frequency in the brain tissue specimens compared to the other human herpesviruses investigated in this study (HHV-6A, CMV, and EBV). Figure 2 shows HHV-6B, EBV and CMV viral loads in each brain tissue specimen. HHV-6B was the most frequently detected virus among the brain specimens, with viral loads ranging from less than 100 to greater than 20,000 copies per million cells. HHV-6B was detected in 3/19 (15.8 %) FFPE GBM samples, 3/20 (15 %) OCT GBM samples, 2/10 (20 %) OCT astrocytoma grade III, and 2/32 (6.2 %) fresh frozen control samples (Table 3). However, HHV-6B was also detected in a low number of brain tissues from non-neurological disease controls (2/49, 4.1 %),

| Table 2 ddPCR assay primers and probes |
|----------------------------------------|
| Forward primer (5’-3’) | Reverse primer (5’-3’) | Probe |
| HHV-6A u57 | CCGTGGGATCGTCTAAAATTATAGTGT | CCACACTAGTCCGGACGGATAA | FAM – CTGGAAGCTGATATAGG – MGBNFQ |
| HHV-6B u57 | CCGTGGGATCGTCTAAAATTATAGTGT | CCACACTAGTCCGGACGGATAA | VIC – CTGGAGCTGTACACAG – MGBNFQ |
| CMV u55 | TGGGCGAGGACACAGGA | TGAGGAAGATGACATG | FAM – TGCGAACCAGCAGGACGTGAGG – 3BHQ |
| EBV lmp1 | AAGTCAAAAGCAACACAGCCAAG | GCATCGGAGTCGTGTG | FAM – AGCTGTACCCCAGTGGAGG – MGBNFQ |
| RPP30 | GATTTGAGGACCTCGGAGG | GCGGCTGTCTCCACAAGT | VIC – CTGACCTAGGCTCTCT – MGBNFQ |

* Ribonuclease P protein subunit p30
and was therefore not statistically significant in the GBM cohort \((p = 0.147)\). HHV-6B was also detected in 2/10 (20 %) astrocytoma grade III samples, but again the proportion compared to controls was not statistically significant \((p = 0.170)\) (Fig. 3). HHV-6A was not detected in any of the astrocytoma or non-neurological disease tissue specimens. HHV-6 is a ubiquitous human herpesvirus in the adult population and the CNS has been suggested as a site of viral latency and reactivation, which is consistent with the HHV-6B positivity observed in our non-neurological disease control cohort [30].

**Significantly higher proportion of EBV in GBM**

While high levels of HHV6B could be demonstrated in high-grade astrocytoma cases (grade III and IV), EBV was only detected in the FFPE GBM samples, 4/19 (21.1 %) and not in any controls (Fig. 3 and Table 3) \((p = 0.049)\). These samples had EBV viral loads ranging from less than 1000 to greater than 17,000 copies per million cells (Fig. 2). Most cases did not show co-infection (two or more viruses) by the multiplex ddPCR assay, however two FFPE GBM tumor specimens were positive for both HHV-6B and EBV. Both cases were verified by both multiplex and singleplex assays. Collectively, the results in this study demonstrated that HHV-6B and EBV, but not CMV, could be amplified from high-grade astrocytomas using a human herpesvirus multiplex ddPCR.

**Discussion**

In recent years, many studies of herpesviruses and brain tumors have examined the association between CMV...
and high-grade astrocytomas, but the relationship is still controversial [31]. Also, no previous study has systematically examined CMV, HHV-6A, HHV-6B, and EBV viral DNA in low- and high-grade astrocytomas. The human herpesviruses have the ability to become latent in specific host cell types, primarily in the CNS and lymphoid tissue [32]. A review of recent studies that used immunohistochemistry (IHC), in situ hybridization (ISH), and PCR to detect CMV in GBM tumor specimens showed that results vary from undetected to 100 % positivity [18]. IHC and PCR each focus on different molecular targets, so detection selectivity discrepancies might be contributing to discordant results. Both techniques have their respective advantages and disadvantages. For instance, the interpretation of IHC is complicated due to background pigments, such as hematoidin, hemosiderin, formalin precipitates, and unspecific staining [5]. While PCR only focuses on a selected genomic sequence, off target amplification may result in false positives, and negative PCR results, i.e. the non-amplification of a specific amplicon, cannot be interpreted as the absence of the viral genome.

The absence of CMV in the GBM samples in this present study does not support a CMV genomic DNA and glioblastoma association, in contrast to other studies that have reported a high prevalence of CMV genomic

|                      | CMV | HHV-6A | HHV-6B | EBV |
|----------------------|-----|--------|--------|-----|
| **FFPE-Preserved Tissue** |     |        |        |     |
| Astrocytoma Grade IV (n = 19) | 0/19 | 0/19 | 3/19 (15.8 %) | 4/19 (21.1 %) |
| Astrocytoma Grade III (n = 2) | 0/2 | 0/2 | 0/2 | 0/2 |
| Astrocytoma Grade II (n = 1) | 0/1 | 0/1 | 0/1 | 0/1 |
| Astrocytoma Grade I (n = 4) | 0/4 | 0/4 | 0/4 | 0/4 |
| Control (n = 17) | 1/17 (5.9 %) | 0/17 | 0/17 | 0/17 |
| **OCT-Preserved Tissue** |     |        |        |     |
| Astrocytoma Grade IV (n = 20) | 0/20 | 0/20 | 3/20 (15 %) | 0/20 |
| Astrocytoma Grade III (n = 10) | 0/10 | 0/10 | 2/10 (20 %) | 0/10 |
| **Fresh Frozen Tissue** |     |        |        |     |
| Astrocytoma Grade IV (n = 6) | 0/6 | 0/6 | 0/6 | 0/6 |
| Astrocytoma Grade II (n = 1) | 0/1 | 0/1 | 0/1 | 0/1 |
| Control (n = 32) | 0/32 | 0/32 | 2/32 (6.2 %) | 0/32 |
DNA in glioblastoma by PCR [33–35]. Most studies have utilized either a protein or a genomic sequence targeting technique, but not both, to detect CMV. A few studies have proposed that certain onco-viruses might trigger viral DNA recombinogenic activities, which could promote oncogenesis with the secondary loss of the viral genome in tumor cells [36, 37]. Viruses that initiate such “hit and run oncogenesis” in the host may be absent at the time of screening.

Other than screening for known viral sequences or using viral-specific IHC assays, a less biased approach would be to sequence brain tumors and search for viral or non-human nucleic acid sequences, for example using a next-generation sequencing platform [38]. With this approach, a report in 2014 demonstrated EBV and HHV-6 viral sequences in 5/21 (24 %) and 1/21 (5 %) of GBM cases, respectively [16]. These viral positivity levels are consistent with the results of this present study, which detected EBV and HHV-6B in 4/45 (8.9 %) and 6/45 (13.3 %) of GBM cases, respectively. However, since the 2014 study did not investigate a control cohort, this limited the interpretation of the roles of EBV and HHV-6 in their GBM cohort.

Although to our knowledge no studies have specifically investigated HHV-6B in glioblastoma, some studies have suggested the involvement of HHV-6 in patients with gliomas. A 2012 study reported 17 of 40 (42.5 %) glioma samples with detectable HHV-6, compared to one of 13 (7.7 %) controls, using nested-PCR [8]. Furthermore, among the glioma cohort, 7/14 GBM (50 %) were HHV-6 positive. In a separate 2009 study, Crawford and colleagues reported a three-fold increase in HHV-6 positivity by IHC in glial tumors compared to non-glial tumors in an adult cohort, and 14/30 (46.7 %) of CNS tumors were HHV-6 positive by nested-PCR compared to 0/25 control brains [39]. While these data suggest the involvement of HHV-6 in at least a subset of brain tumors, the specific potential oncogenic mechanisms of HHV-6 are not fully understood.

We found EBV to be present at a significantly higher frequency in GBM compared to controls. EBV is an oncovirus that is responsible for the development of Hodgkin’s lymphoma, nasopharyngeal carcinoma and Burkitt's lymphoma. However, few studies have examined the relationship between EBV and astrocytomas, specifically. In a study by Neves et al. in 2012, EBV was the most frequently detected human herpesviruses in pilocytic astrocytoma (WHO grade I) by PCR, but at fairly low levels (<100/100 ng cellular DNA) [40]. Neves and colleagues detected only one sample with CMV, but did not detect any HHV-6. Further epidemiological and molecular studies are needed to investigate the role of EBV in astrocytomas.

Among the glioblastoma cohort in this present study, there were two cases with co-infection of EBV and HHV-6B. Currently, no study has reported EBV and HHV-6 co-infection in glioblastoma, though this has been observed in suspected viral CNS disease samples [41, 42]. Several in-vitro studies indicate that HHV-6 may activate EBV expression, which might promote EBV-associated diseases later in life [43, 44]. A 2015 study reported two encephalitis cases with HHV-6 and EBV co-infection detected by PCR [45]. However, the coinfection of these two herpesviruses in our case cohort cannot be seen as causal agents of the astrocytoma. The detection of HHV-6B and EBV could be a mere consequence of molecular events within the tumor that may be associated with reactivation of latent virus [46].

In our cohort, the sensitivity of multiple human herpesvirus detection did not vary with the biopreservation method. All preservation methods were comparable in terms of virus detection, though fresh-frozen remains the most ideal for viral detection. Some studies have raised concerns about the possibility of DNA degradation upon long-term storage in FFPE. The vast majority of studies used FFPE-preserved tissues for the detection of viral protein or DNA. However, in a study that examined the quality of FFPE extracted DNA, no significant differences were found between DNA extracted from FFPE tissue blocks that had been stored for less than one year and FFPE tissue blocks that had been stored for 1–11 years [47].

Lastly, the ddPCR multiplex assay is a highly precise viral diagnostic tool that enables the absolute quantification of multiple viral target regions [48, 49]. Although multiplex qPCR has a shorter analysis time, high sensitivity, and a broad dynamic range, the multiplex ddPCR assay has lower variability, outstanding accuracy, and provides better quality of quantification in the multiplex assay [49]. A study reported by Hayden in 2013 compared quantitative real-time PCR (qRT-PCR) and ddPCR for the detection of CMV in clinical samples, and reported that ddPCR showed less variability when detecting samples at higher concentrations [50]. Overall, the study indicated that ddPCR is an accurate assay for detecting CMV viral loads in clinical samples. In our study, we compared a multiplex ddPCR assay with a singleplex ddPCR assay, and there was no significant difference in quantification or qualification ability. However, any type of PCR system is prone to the misclassification of viral detection due to low sensitivity or specificity of the primer/probe set. As a result, optimization of the primers and probe becomes critical. Regardless of the PCR type, a multiplex assay can be adopted as a diagnostic tool that quantifies multiple viral targets, while conserving samples in a clinical setting.
Conclusion
Despite the availability of advanced genomic technology, establishing an association between ubiquitous viruses and primary brain tumors remains challenging. Once again, the present study is a cross-sectional screening of multiple herpesviruses in low- and high-grade astrocytoma specimens. Other detection methods and study designs should be used before making firm conclusions about the association of CMV with glioblastoma.

However, these results have shown that several other herpesviruses may be associated with high-grade astrocytomas. Moreover, HHV-6 and EBV need to be further investigated in other types of primary brain cancers and their possible mechanisms of pathogenesis further explored. Ultimately, blinded and randomized clinical trials of anti-viral agents or other anti-viral intervention strategies may be the only way to describe an association between herpesviruses and GBM or other cancers.

Acknowledgments
Special thanks to Barbara Ikehr from the National Institute of Neurological Disorders and Stroke for providing access to brain tissue specimens; Dr. Ningping Feng and Dr. Barbara Lipska from the National Institute of Mental Health for providing non-neurological disease control brain specimens and technical support; Dr. Anamaria Calberg-Poley from Children’s National Medical Center for CMV plasmid positive controls. CTML is currently a trainee at the Duke University Clinical Research Training Program, 8 Seafar Center Drive, Durham, North Carolina, USA 27703.

Funding
This work was supported by the intramural research program of NINDS, and the funders had no role in study design, data collection, data analysis, decision to publish or manuscript preparation.

Authors’ contributions
CTML carried out the ddPCR assay, participated in the brain tissue preparation, designed the study, performed the statistical analysis, and drafted the manuscript. EL participated in the brain tissue preparation, designed the study, and drafted the manuscript. MIAS collected the brain tissue specimens for the study. SJ participated in the design and the coordination of the study and drafted the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Author details
1The National Institute of Neurological Disorders and Stroke, National Institutes of Health, BG 10 RM SC103 10 Center Dr., Bethesda, MD 20892, USA. 2School of Medicine and Health Sciences, The George Washington University, Ross Hall 2300 Eye Street, NW, Washington, DC 20037, USA.

Received: 31 March 2016 Accepted: 25 May 2016
Published online: 26 July 2016

References
1. Cohen AL, Colman H. Gliona biology and molecular markers. Cancer Treat Res. 2015;163:15–30.
2. Binder DC, Davis AA, Wainwright DA. Immunotherapy for cancer in the central nervous system: Current and future directions. Oncoimmunology. 2016;5:1103277.
3. Krex D, Klink B, Hartmann C, et al. Long-term survival with glioblastoma multiforme. Brain. 2007;130:2596–606.
4. Allifieris C, Trafalis DT. Glioblastoma multiforme: Pathogenesis and treatment. Pharmacolet Ther. 2015;152:63–82.
5. Baumgarten P, Michaelis M, Rothweiler F, et al. Human cytomegalovirus infection in tumor cells of the nervous system is not detectable with standardized pathologic-virological diagnostics. Neuro Oncol. 2014;16:1469–77.
6. Shamm HA, Kadhim HS, Hussain AR, et al. Detection of human cytomegalovirus in different histopathological types of gliona in Iraqi patients. Biomed Res Int. 2015;2015:642652.
7. Wick W, Platten M. CMV infection and gliona, a highly controversial concept struggling in the clinical arena. Neuro Oncol. 2014;16:332–3.
8. Chi J, Gu B, Zhang C, et al. Human herpesvirus 6 latent infection in patients with glioma. J Infect Dis. 2012;206:1394–8.
9. Crawford JR, Santi MR, Theranrisdottir HK, et al. Detection of human herpesvirus-6 variants in pediatric brain tumors: association of vial antigen in low grade gliona. J Clin Virol. 2009;46:367–42.
10. Kofman A, Marcinkiewicz L, Dupant E, et al. The roles of viruses in brain tumor initiation and oncomodulation. J Neuroonc. 2011;105:451–66.
11. Epstein LG, Shinnar S, Hesdorffer DC, et al. Human herpesvirus 6 and 7 in 7 in febrile status epilepticus: the FEAST study. Epilepsia. 2012;53:1482–18.
12. Li JI, Lei D, Peng F, et al. Detection of human herpes virus 6B in patients with mesial temporal lobe epilepsy in West China and the possible association with elevated NF-kappaB expression. Epilepsia. Res. 2011;94:1–9.
13. Hill JA, Venna N. Human herpesvirus 6 and the nervous system. Handb Clin Neurol. 2014;123:327–55.
14. Cesnaro E. Cmamaherpesvirus and lymphoproliferative disorders in immunocompromised patients. Cancer Lett. 2011;305:163–74.
15. Bienemann K, Borkhardt A, Klapper W, Ochslie I. High incidence of EBV positive Hodgkin Lymphoma and Hodgkin-like B-cell lymphoproliferations with EBV-latency profile 2 in children with ITK deficiency. Histopathology. 2015;67:607–16.
16. Cimino PJ, Zhao G, Wang D, Sehn JK, Lewis Jr JS, Duncavage EJ. Detection of viral pathogens in high grade gliona from unmapped next-generation sequencing data. Exp Mol Pathol. 2014;96:610–5.
17. Mitchell DA, Barich KA, Gunn MD, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 2015;519:366–9.
18. Solomon IH, Ramkisson SH, Milner Jr DA, Folkert RD. Cytomegalovirus and glioblastoma: a review of evidence for their association and implications for testing and treatment. J Neuropatol Exp Neurol. 2014;73:904–8.
19. Hudecova I. Digital PCR, analysis of circulating nucleic acids. Clin Biochem. 2015;48:945–56.
20. Rad B. QX100 Droplet Digital PCR System. In: Rad BIO, editor. QX100™ Droplet Digital™ PCR System Brochure RC. 2015.
21. Brunetto GS, Massoud R, Leibovitch EC, et al. Digital droplet PCR (ddPCR) for the precise quantification of human T-lymphotropic virus 1 proviral loads in peripheral blood and cerebrospinal fluid of HAM/TSP patients and identification of viral mutations. J Neurovirol. 2014;20:341–51.
22. Devonshire AS, Honeyborne I, Gutteridge A, et al. Highly reproducible absolute quantification of Mycobacterium tuberculosis complex by digital PCR. Anal Chem. 2015;87:3706–13.
23. Boehme P, Stelberger T, Solanki M, et al. Standard free droplet digital polymerase chain reaction as a new tool for the quality control of high-capacity adenoviral vectors in small-scale preparations. Hum Gene Ther Methods. 2015;26:25–34.
24. Sedlak RH, Cook L, Cheng A, Magaret A, Jerome KR. Clinical utility of droplet digital PCR for human cytomegalovirus. J Clin Microbiol. 2014;52:2844–8.
25. Leibovitch EC, Brunetto GS, Caruso B, et al. Coinfection of Human Cytomeglovirus and Epstein-Barr virus in the brain tissue. J Neuropathol Exp Neurol. 2014;73:904–8.
26. Ryschkewitsch CF, Jensen PN, Major EO. Multiplex qPCR assay for ultra sensitive detection of JCV DNA with simultaneous identification of genotypes that discriminate non-virulent from virulent variants. J Clin Virol. 2013;57:243–8.
27. Serafini B, Boscarelli B, Franciotta D, et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med. 2007;204:2899–912.
28. Cortez KJ, Fischer SH, Fahle GA, et al. Clinical trial of quantitative real-time polymerase chain reaction for detection of cytomegalovirus in peripheral blood of allogeneic hematopoietic stem-cell transplant recipients. J Infect Dis. 2003;188:967–72.
29. Ranganathan P, Clark PA, Kuo JS, Salamat MS, Kaleja RF. Significant association of multiple human cytomegalovirus genomic Loci with glioblastoma multiforme samples. J Virol. 2012;86:654–64.
30. Ansari A, Li S, Abzug MJ, Weinberg A. Human herpesviruses 6 and 7 and central nervous system infection in children. Emerg Infect Dis. 2004;10:1450–4.
31. Lawler SE. Cytomegalovirus and glioblastoma; controversies and opportunities. J Neurooncol. 2015;123:465–71.
32. Cobbs CS. Cytomegalovirus and brain tumor: epidemiology, biology and therapeutic aspects. Curr Opin Oncol. 2013;25:682–8.
33. Bhattacharjee B, Renzette N, Kowalk TF. Genetic analysis of cytomegalovirus in malignant gliomas. J Virol. 2012;86:818–24.
34. dos Santos CJ, Stangherlin LM, Figueiredo EG, Correa C, Teixeira MJ, da Silva MC. High prevalence of HCMV and viral load in tumor tissues and peripheral blood of glioblastoma multiforme patients. J Med Virol. 2014;86:1953–61.
35. Fonseca RF, Kawamura MT, Oliveira JA, Teixeira A, Alves G, Mda Carvalho G. The prevalence of human cytomegalovirus DNA in gliomas of Brazilian patients. Mem Inst Oswaldo Cruz. 2012;107:953–4.
36. Houben R, Grimm J, Willmes C, Weinram R, Becker JC, Schrama D. Merkel cell carcinoma and Merkel cell polyomavirus: evidence for hit-and-run oncogenesis. J Invest Dermatol. 2012;132:254–6.
37. Niller HH, Wolf H, Minarovits J. Viral hit and run-oncogenesis: genetic and epigenetic scenarios. Cancer Lett. 2011;305:200–17.
38. Tang KW, Alaei-Mahabadi B, Samuelsson T, Lindh M, Larsson E. The landscape of viral expression and host gene fusion and adaptation in human cancer. Nat Commun. 2013;4:2513.
39. Crawford JR, Santi MR, Cornelison R, Sallinen SL, Haapalalo H, MacDonald TJ. Detection of human herpesvirus-6 in adult central nervous system tumors: predominance of early and late viral antigens in glial tumors. J Neurooncol. 2009;95:49–60.
40. Neves AM, Thompson G, Carvalheira J, et al. Detection and quantitative analysis of human herpesvirus in pilocytic astrocytoma. Brain Res. 2008;1221:108–14.
41. Tang YW, Espy MJ, Persing DH, Smith TF. Molecular evidence and clinical significance of herpesvirus coinfection in the central nervous system. J Clin Microbiol. 1997;35:2869–72.
42. Calvario A, Bozzi A, Scarasciulli M, et al. Herpes Consensus PCR test: a useful diagnostic approach to the screening of viral diseases of the central nervous system. J Clin Microbiol. 2002;35:1571–8.
43. Cuomo L, Trivedi P, de Grazia U, et al. Upregulation of Epstein-Barr virus-encoded latent membrane protein by human herpesvirus 6 superinfection of EBV-carrying Burkitt lymphoma cells. J Med Virol. 1998;55:219–26.
44. Flamand L, Stefanescu I, Ablashi DV, Menezes J. Activation of the Epstein-Barr virus replicative cycle by human herpesvirus 6. J Virol. 1993;67:6768–77.
45. Rimienti CA, De Oliveira RS, de Almeida Bonatelli MQ, Nucci A, Costa SC, Bonon SH. Human herpesvirus infections of the central nervous system: laboratory diagnosis based on DNA detection by nested PCR in plasma and cerebrospinal fluid samples. J Med Virol. 2015;87:648–55.
46. Hollisberg P, Kusk M, Bech E, Hansen HJ, Jakobsen J, Haahr S. Presence of Epstein-Barr virus and human herpesvirus 6B DNA in multiple sclerosis patients: associations with disease activity. Acta Neurol Scand. 2005;112:395–402.
47. Kokkat TJ, Patel MS, McGarvey D, Liuoli VA, Baloch ZW. Archived formalin-fixed paraffin-embedded (FFPE) blocks: A valuable underexploited resource for extraction of DNA, RNA, and protein. Biopreserv Biobank. 2013;11:101–6.
48. Prettio D, Maar D, Yrigollen CM, Regan J, Tassone F. Screening newborn blood spots for 22q11.2 deletion syndrome using multiplex droplet digital PCR. Clin Chem. 2015;61:182–90.
49. Tu SH, Chen EY, Gin KY. Comparison of Quantitative PCR and Droplet Digital PCR Multiplex Assays for Two Genera of Bloom-Forming Cyanobacteria, Cyanobiospumopsis and Microcystis. Appl Environ Microbiol. 2015;81:5203–11.
50. Hayden RT, Gu Z, Ingersoll J, et al. Comparison of droplet digital PCR to real-time PCR for quantitative detection of cytomegalovirus. J Clin Microbiol. 2013;51:540–6.